Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AMT-260 by UniQure for Epilepsy: Likelihood of Approval
AMT-260 is under clinical development by UniQure and currently in Phase II for Epilepsy. According to GlobalData, Phase II drugs...